Alembic Pharmaceuticals Ltd announced its financial results for the second quarter (Q2 FY25), posting a solid performance across key metrics.
The company’s net profit jumped 21% year-on-year to ₹185 crore, compared to ₹153 crore in the same period last year, supported by strong revenue growth and improved margins.
Revenue for the quarter stood at ₹1,910 crore, marking a 16% rise from ₹1,648 crore a year ago. EBITDA surged 32% to ₹315.3 crore versus ₹239.3 crore in Q2 FY24, reflecting operational efficiency and cost control measures. EBITDA margin also improved to 16.5% from 14.5% last year.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
